Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 8-week, Multi-Centre, Open-label, Non-comparative, Phase IV Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR) With Daily Dose 400mg-800mg in the Treatment of Acute Schizophrenic Patients

NCT00779506 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00779506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00779506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 8-week, Multi-Centre, Open-label, Non-comparative, Phase IV Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR) With Daily Dose 400mg-800mg in the Treatment of Acute Schizophrenic Patients
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2008
Completion date
July 31, 2009
Enrollment
96 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia